These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38100909)

  • 1. Generation of two induced pluripotent stem cell lines from hereditary amyloidosis patients with polyneuropathy carrying heterozygous transthyretin (TTR) mutation.
    Melesio J; Bonilauri B; Li A; Pang PD; Liao R; Witteles RM; Wu JC; Sallam K
    Stem Cell Res; 2024 Feb; 74():103265. PubMed ID: 38100909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of two induced pluripotent stem cell lines from patients with cardiac amyloidosis carrying heterozygous transthyretin (TTR) mutation.
    Bonilauri B; Shin HS; Htet M; Yan CD; Witteles RM; Sallam K; Wu JC
    Stem Cell Res; 2023 Oct; 72():103215. PubMed ID: 37788558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transthyretin deposition in familial amyloidotic polyneuropathy.
    Saraiva MJ; Magalhaes J; Ferreira N; Almeida MR
    Curr Med Chem; 2012; 19(15):2304-11. PubMed ID: 22471982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of an induced pluripotent stem cell line from a patient with hereditary transthyretin amyloidosis carrying transthyretin (TTR) mutation p.Phe53Val.
    Shan H; Ye J; Hai Ping X; XinYue H; ShuYang Z
    Stem Cell Res; 2020 Oct; 48():101940. PubMed ID: 32858486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced pluripotent stem cell modeling of multisystemic, hereditary transthyretin amyloidosis.
    Leung A; Nah SK; Reid W; Ebata A; Koch CM; Monti S; Genereux JC; Wiseman RL; Wolozin B; Connors LH; Berk JL; Seldin DC; Mostoslavsky G; Kotton DN; Murphy GJ
    Stem Cell Reports; 2013; 1(5):451-63. PubMed ID: 24286032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of an induced pluripotent stem cell line PUMCHi004-A from a hereditary transthyretin amyloid cardiomyopathy patient with transthyretin (TTR) p.Asp38Asn mutation.
    He S; Jin Y; Tian Z; Hua T; Xing H; Zhuang S; He X; Li H; Wang L; Zhang S
    Stem Cell Res; 2020 Dec; 49():102022. PubMed ID: 33038745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics.
    Giadone RM; Rosarda JD; Akepati PR; Thomas AC; Boldbaatar B; James MF; Wilson AA; Sanchorawala V; Connors LH; Berk JL; Wiseman RL; Murphy GJ
    Amyloid; 2018 Sep; 25(3):148-155. PubMed ID: 30032658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis: A Review in Transthyretin Amyloidosis with Polyneuropathy.
    Lamb YN; Deeks ED
    Drugs; 2019 Jun; 79(8):863-874. PubMed ID: 31098895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.
    Giadone RM; Liberti DC; Matte TM; Rosarda JD; Torres-Arancivia C; Ghosh S; Diedrich JK; Pankow S; Skvir N; Jean JC; Yates JR; Wilson AA; Connors LH; Kotton DN; Wiseman RL; Murphy GJ
    Stem Cell Reports; 2020 Aug; 15(2):515-528. PubMed ID: 32735824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hereditary transthyretin-related amyloidosis is frequent in polyneuropathy and cardiomyopathy of no obvious aetiology.
    Skrahina V; Grittner U; Beetz C; Skripuletz T; Juenemann M; Krämer HH; Hahn K; Rieth A; Schaechinger V; Patten M; Tanislav C; Achenbach S; Assmus B; Knebel F; Gingele S; Skrahin A; Hartkamp J; Förster TM; Roesner S; Pereira C; Rolfs A
    Ann Med; 2021 Dec; 53(1):1787-1796. PubMed ID: 34658264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan.
    Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y
    Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.
    Adams D; Ando Y; Beirão JM; Coelho T; Gertz MA; Gillmore JD; Hawkins PN; Lousada I; Suhr OB; Merlini G
    J Neurol; 2021 Jun; 268(6):2109-2122. PubMed ID: 31907599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Red flags and adjusted suspicion index for distinguishing hereditary transthyretin amyloid polyneuropathy from idiopathic axonal polyneuropathy.
    Warendorf JK; van der Star GM; Dooijes D; Notermans NC; Vrancken AFJE
    Neurol Sci; 2023 Oct; 44(10):3679-3685. PubMed ID: 37266816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.
    Lavigne-Moreira C; Marques VD; Gonçalves MVM; de Oliveira MF; Tomaselli PJ; Nunez JC; do Nascimento OJM; Barreira AA; Marques W
    J Peripher Nerv Syst; 2018 Jun; 23(2):134-137. PubMed ID: 29520877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.
    Waddington-Cruz M; Ackermann EJ; Polydefkis M; Heitner SB; Dyck PJ; Barroso FA; Wang AK; Berk JL; Dyck PJB; Monia BP; Hughes SG; Tai L; Jesse Kwoh T; Jung SW; Coelho T; Benson MD; Gertz MA
    Amyloid; 2018 Sep; 25(3):180-188. PubMed ID: 30169969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
    Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
    Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells.
    Isono K; Jono H; Ohya Y; Shiraki N; Yamazoe T; Sugasaki A; Era T; Fusaki N; Tasaki M; Ueda M; Shinriki S; Inomata Y; Kume S; Ando Y
    Stem Cell Res; 2014 Mar; 12(2):574-83. PubMed ID: 24531302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
    Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.